H.C. Wainwright analyst Raghuram Selvaraju reiterated a Neutral rating on Oramed Pharma (NASDAQ: ORMP).The analyst commented: "Oramed's Chinese partner, Hefei ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE